• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

Bayer

Dorzagliatin: Drug That Can “Cure” Diabetes
Posted inClinical Trials, Metabolism

Dorzagliatin: Drug That Can “Cure” Diabetes

November 13, 2022November 13, 2022

Hua Medicine has figured out how to bring type 2 diabetes mellitus into long-term and sustained remission.

Kerendia: New Drug for Diabetic Kidney Disease
Posted inMetabolism, New Drugs, Regulatory

Kerendia: New Drug for Diabetic Kidney Disease

February 16, 2022September 8, 2022

Finerenone for the treatment of diabetic nephropathy, a chronic kidney disease associated with type 2 diabetes mellitus.

Vabysmo: New Drug for Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Posted inNew Drugs, Regulatory

Vabysmo: New Drug for Wet Age-Related Macular Degeneration and Diabetic Macular Edema

February 1, 2022September 8, 2022

Faricimab by Roche is a strong competitor to Eylea.

liver
Posted inOncology, Research

Tecentriq Plus Avastin: Most Effective Treatment for Unresectable Hepatocellular Carcinoma

January 30, 2022September 8, 2022

Atezolizumab with bevacizumab: a powerful immunotherapy approach for first-line therapy of liver cancer.

cough
Posted inNeuroscience, New Drugs, Regulatory

Lyfnua: First Drug for Refractory or Unexplained Chronic Cough

January 25, 2022September 8, 2022

Gefapixant will reduce cough frequency, thereby improving patients’ quality of life.

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News